Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...
Hosted on MSN1y
Teva to divest API unit to focus on core business strengths
Teva (NYSE:TEVA) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths. "The intent to divest TAPI ...